Pharmacokinetics of pantoprazole in man.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8738854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

  2006cited by this paper
• Lack of pharmacokinetic interaction as an equivalence problem.

  1996cited by this paper
• Pantoprazole does not interact with nifedipine in man under steady-state conditions.

  1996cited by this paper
• Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.

  1995cited by this paper
• No influence of pantoprazole on the pharmacokinetics of phenytoin.

  1995cited by this paper
• The continuing development of proton pump inhibitors with particular reference to pantoprazole

  1995cited by this paper
• Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.

  1995cited by this paper
• Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.

  1995cited by this paper
• A review of treatment of duodenal and gastric ulcers‐‐pantoprazole vs. omeprazole.

  1994cited by this paper
• Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer

  1994cited by this paper
• Lack of pantoprazole drug interactions in man.

  1994cited by this paper
• Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.

  1994cited by this paper
• Pharmacokinetics‐‐a relevant factor for the choice of a drug?

  1994cited by this paper
• The interaction of proton pump inhibitors with cytochromes P450.

  1994cited by this paper
• Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.

  1994cited by this paper
• The rationale of acid suppression in the treatment of acid‐related disease.

  1994cited by this paper
• Presentation of results from bioequivalence studies.

  1992cited by this paper
• (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.

  1992cited by this paper
• Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.

  1992cited by this paper
• Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.

  1991cited by this paper
• Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

  1991cited by this paper
• In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.

  1991cited by this paper
• The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.

  1991cited by this paper
• Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

  1990cited by this paper
• Single intravenous administration of the H+, K+‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man

  1990cited by this paper
• Effect of repeated oral administration of BY 1023/SK&F 96022 – a new substituted benzimidazole derivative – on pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man

  1990cited by this paper
• BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.

  1990cited by this paper
• Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

  1990cited by this paper
• Variations in left ventricular volume alter myocardial oxygen consumption more at low than at high inotropy.

  1990cited by this paper
• Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.

  1990cited by this paper
• High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up.

  1990cited by this paper
• Omeprazole: pharmacokinetics and metabolism in man.

  1989cited by this paper
• Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.

  1988cited by this paper
• Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

  1985cited by this paper

• The Utilization of Externally Sourced Data and Data Collected and Analyzed from Previously Completed Studies Using Modelling and Simulation and Other Methodologies to Support Pediatric-Focused Regulatory Commitments

  2026cites this paper
• Comparative pharmacokinetics of intravenous and subcutaneous pantoprazole in sheep and goats.

  2024cites this paper
• Combining Advanced Analytical Methodologies to Uncover Suspect PFAS and Fluorinated Pharmaceutical Contributions to Extractable Organic Fluorine in Human Serum (Tromsø Study)

  2024cites this paper
• Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations

  2024cites this paper
• Associations between enteral nutrition and outcomes in the SUP‐ICU trial: Results of exploratory post hoc analyses

  2024cites this paper
• Personalized Treatments Based on Laryngopharyngeal Reflux Patient Profiles: A Narrative Review

  2023cites this paper
• Treating and Managing Laryngopharyngeal Reflux Disease in the Over 65s: Evidence to Date

  2022cites this paper
• The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination

  2021cites this paper
• Gastroesophageal Reflux Disease and Barrett Esophagus in the Elderly.

  2021cites this paper
• Binding of omeprazole to protein targets identified by monoclonal antibodies

  2020cites this paper
• Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

  2020cites this paper
• Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial.

  2020cites this paper
• Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

  2018cites this paper
• Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study

  2018cites this paper
• Safe use of proton pump inhibitors in patients with cirrhosis

  2018cites this paper
• Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples

  2016cites this paper
• Histamine 2 Receptor Antagonists and Proton Pump Inhibitors

  2016cites this paper
• High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study.

  2016cites this paper
• In Vitro Effects of Pantoprazole on Platelet Aggregation in Blood Samples From Clopidogrel and Aspirin-treated Patients

  2016cites this paper
• The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans.

  2015cites this paper
• Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression

  2015cites this paper
• Reflux and acid peptic diseases in the elderly.

  2014cites this paper
• Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.

  2014cites this paper
• Potentiometric determination of pantoprazole using an ion-selective sensor based on polypyrrole doped films.

  2014cites this paper
• Stereoselective Interaction of Pantoprazole with ABCG2. I. Drug Accumulation in Rat Milk

  2012cites this paper
• The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease

  2012cites this paper
• Pantoprazole

  2012cites this paper
• Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux Disease

  2011cites this paper
• A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

  2011cites this paper
• The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.

  2011cites this paper
• Efficacy and pharmacokinetics of pantoprazole in alpacas.

  2010cites this paper
• Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

  2010cites this paper
• Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

  2009cites this paper
• Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study

  2009cites this paper
• Helicobacter pylori eradication: role of individual therapy constituents and therapy duration

  2009cites this paper
• Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

  2009cites this paper
• Proton Pump Inhibitors Reduce Mycophenolate Exposure in Heart Transplant Recipients—A Prospective Case‐Controlled Study

  2009cites this paper
• Pharmacology of proton pump inhibitors

  2008cites this paper
• Single‐Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents

  2008cites this paper
• Gastrointestinal medications.

  2007cites this paper
• Pantoprazole: a proton pump inhibitor with oral and intravenous formulations

  2007cites this paper
• Intravenous Versus High-Dose Oral Proton Pump Inhibitor Therapy After Endoscopic Hemostasis of High-Risk Lesions in Patients with Acute Nonvariceal Upper Gastrointestinal Bleeding

  2007cites this paper
• Simultaneous estimation of pantoprazole and domperidone in pure powder and a pharmaceutical formulation by high-perfomance liquid chromatography and high-performance thin-layer chromatography methods.

  2007cites this paper
• Recent advances in proton pump inhibitors and management of acid-peptic disorders.

  2007cites this paper
• Bio equivalence of Two Enteric Coated Formulations of Pantoprazole in Healthy Volunteers under Fasting and Fed Conditions

  2007cites this paper
• Safety of potent gastric acid inhibition.

  2005cites this paper
• High-performance liquid chromatography method for the quantification of pantoprazole in human plasma.

  2005cites this paper
• Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels

  2005cites this paper
• Role of pantoprazole in the treatment of gastro-oesophageal reflux disease

  2005cites this paper
• Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors

  2005cites this paper
• Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole.

  2004cites this paper
• Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.

  2004cites this paper
• Determination of Pantoprazole in Human Plasma by LC-MS-MS Using Lansoprazole as Internal Standard

  2004cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper
• Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

  2003cites this paper
• Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution.

  2003cites this paper
• Pharmacogenetics of the Proton Pump Inhibitors: A Systematic Review

  2003cites this paper
• Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

  2003cites this paper
• Treatment of Acid-Related Diseases in the Elderly with Emphasis on the Use of Proton Pump Inhibitors

  2002cites this paper
• Agranulocytosis Associated with Initiation of Famotidine Therapy

  2002cites this paper
• Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.

  2001cites this paper
• Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

  2001cites this paper
• Pharmacodynamic Modeling of Pantoprazole's Irreversible Effect on Gastric Acid Secretion in Humans and Rats

  2001cites this paper
• Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors

  2000cites this paper
• Clinical experience with pantoprazole in gastroesophageal reflux disease.

  2000cites this paper
• Pantoprazole: a new proton pump inhibitor.

  2000cites this paper
• Pantoprazole lacks induction of CYP1A2 activity in man.

  1999cites this paper
• Review article: acid suppression in non‐variceal acute upper gastrointestinal bleeding

  1999cites this paper
• Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man.

  1999cites this paper
• Lack of Pharmacokinetic Interaction between Oral Pantoprazole and Cisapride in Healthy Adults

  1999cites this paper
• Pharmacokinetics of pantoprazole in patients with end-stage renal failure.

  1998cites this paper
• Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S‐mephenytoin 4′‐hydroxylation phenotype and genotype *

  1997cites this paper
• Lack of pantoprazole drug interactions in man: an updated review.

  1996cites this paper
• Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.

  1996cites this paper
• Lack of pantoprazole drug interactions in man: an updated review.

  1996cites this paper